6,731 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Bought by American Century Companies Inc.

American Century Companies Inc. bought a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 6,731 shares of the company's stock, valued at approximately $570,000.

Several other institutional investors and hedge funds have also bought and sold shares of AXSM. Assetmark Inc. purchased a new position in Axsome Therapeutics in the 4th quarter worth approximately $52,000. R Squared Ltd purchased a new position in Axsome Therapeutics in the fourth quarter worth $64,000. KBC Group NV increased its stake in Axsome Therapeutics by 40.5% in the fourth quarter. KBC Group NV now owns 1,336 shares of the company's stock valued at $113,000 after acquiring an additional 385 shares during the last quarter. Xponance Inc. raised its position in Axsome Therapeutics by 11.6% during the fourth quarter. Xponance Inc. now owns 2,659 shares of the company's stock valued at $225,000 after purchasing an additional 277 shares in the last quarter. Finally, Corient Private Wealth LLC bought a new stake in Axsome Therapeutics during the fourth quarter worth about $239,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Axsome Therapeutics Trading Up 0.3 %

NASDAQ:AXSM traded up $0.30 during mid-day trading on Tuesday, reaching $103.83. 889,131 shares of the company's stock traded hands, compared to its average volume of 680,587. The company has a 50 day moving average price of $119.30 and a 200-day moving average price of $102.17. The firm has a market capitalization of $5.06 billion, a price-to-earnings ratio of -17.33 and a beta of 0.88. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. Axsome Therapeutics, Inc. has a 12-month low of $64.11 and a 12-month high of $139.13.

Remove Ads

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The firm had revenue of $118.77 million for the quarter, compared to analysts' expectations of $117.83 million. On average, sell-side analysts predict that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on AXSM. Mizuho increased their price objective on Axsome Therapeutics from $212.00 to $216.00 and gave the company an "outperform" rating in a research report on Thursday, March 27th. William Blair reissued an "outperform" rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. Royal Bank of Canada upped their price objective on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the company an "outperform" rating in a research note on Wednesday, February 19th. Deutsche Bank Aktiengesellschaft started coverage on shares of Axsome Therapeutics in a report on Tuesday, February 11th. They set a "buy" rating and a $176.00 target price on the stock. Finally, Robert W. Baird boosted their price target on shares of Axsome Therapeutics from $132.00 to $160.00 and gave the stock an "outperform" rating in a research note on Monday, March 3rd. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Axsome Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $169.80.

Insiders Place Their Bets

In other news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the sale, the chief financial officer now owns 42,187 shares of the company's stock, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 22.40% of the company's stock.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.